These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10687724)

  • 1. Myelodysplasia.
    Dansey R
    Curr Opin Oncol; 2000 Jan; 12(1):13-21. PubMed ID: 10687724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelodysplasia: the good, the fair and the ugly.
    Schiffer CA
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):49-55. PubMed ID: 17336254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M
    Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
    Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
    Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of myelodysplastic syndromes in patients receiving concurrent myelosuppressive chemotherapy and pegfilgrastim.
    Covert WM; Murillo JR; Cox JE
    J Oncol Pharm Pract; 2011 Dec; 17(4):366-71. PubMed ID: 20876080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypocellular myelodysplasia.
    Sloand EM
    Hematol Oncol Clin North Am; 2009 Apr; 23(2):347-60. PubMed ID: 19327588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy-related myelodysplastic syndromes, or are they?
    Abou Zahr A; Kavi AM; Mukherjee S; Zeidan AM
    Blood Rev; 2017 May; 31(3):119-128. PubMed ID: 27923516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunosuppressive treatment of the myelodysplastic syndrome].
    Larsen MS; Hasselbalch HC
    Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents.
    Hellström-Lindberg E
    Hematology Am Soc Hematol Educ Program; 2005; ():161-6. PubMed ID: 16304375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes.
    Molldrem JJ; Leifer E; Bahceci E; Saunthararajah Y; Rivera M; Dunbar C; Liu J; Nakamura R; Young NS; Barrett AJ
    Ann Intern Med; 2002 Aug; 137(3):156-63. PubMed ID: 12160363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG).
    De Witte T; Zwaan F; Hermans J; Vernant J; Kolb H; Vossen J; Lönnqvist B; Beelen D; Ferrant A; Gmür J
    Br J Haematol; 1990 Feb; 74(2):151-5. PubMed ID: 2180469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
    Passweg JR; Giagounidis AA; Simcock M; Aul C; Dobbelstein C; Stadler M; Ossenkoppele G; Hofmann WK; Schilling K; Tichelli A; Ganser A
    J Clin Oncol; 2011 Jan; 29(3):303-9. PubMed ID: 21149672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to the treatment of myelodysplasia.
    List AF
    Oncologist; 2002; 7 Suppl 1():39-49. PubMed ID: 11961208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
    Cazzola M
    Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.
    Mishra A; Anasetti C
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S49-52. PubMed ID: 27521324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic Syndromes: Diagnosis and Treatment.
    Steensma DP
    Mayo Clin Proc; 2015 Jul; 90(7):969-83. PubMed ID: 26141335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance and methylation in myelodysplastic syndrome.
    Vidal DO; Lopes LF; Valera ET
    Curr Pharm Biotechnol; 2007 Apr; 8(2):77-81. PubMed ID: 17430155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.